An Open Labeled, Single Centre, Prospective, Clinical Study to Evaluate Efficacy and Safety of ARWL12 Capsule in Patients suffering from Internal Hemorrhoids - NI

Welex Laboratories Pvt Ltd0 个研究点目标入组 38 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Literate males or non-pregnant females, aged 20 to 60 years (both inclusive).
•2.Symptomatic internal hemorrhoids, Grades I & II by direct proctoscopic visualization
•3.Bleeding from hemorrhoids for at least two days prior to randomization
•4.Body mass index of >= 18.5 to <= 36 kg/m2.
•5.Subjects of female gender or non-pregnant, non-lactating females, at least six weeks postpartum. A urine pregnancy test is required for all female subjects unless subject has had a hysterectomy, tubal ligation, or is > 2 years postmenopausal.
•6.Females of child bearing potential who agree to use contraception.
•7.Subjects willing to follow the procedures as per the study protocol and voluntarily sign an informed consent form.

•1.Patients with protruding or irreducible hemorrhoids (grade IV).
•2.Patients with anal fistulas, periproctitis or hemorrhagic diathesis
•3.Patients with current history of Type I or Type II diabetes mellitus.
•4.Patients with severe hepatic, renal or cardiovascular disorders.
•5.Patients with any type of infectious disease.
•6.Patients who have been involved with another experimental drug trial within the past 30 days.
•7.Patients presently diagnosed with cancer.
•8.Patients who have known alcohol and drug abuse.
•9.Patients who require the use of suppositories.
•10.Use of anticoagulants within 30 days prior to Day 1.
•11.Patients on anti-platelet agents or low dose aspirin
•12.Use of over the counter or prescription anti-hemorrhoid agents (allopathic, herbal, homeopathic, Unani, Siddha medicines) within 14 days prior to Day 1.
•13.Patients with blood or urine laboratory values outside the normal limits or those with values considered abnormal in the opinion of the investigator.
•14.Known hypersensitivity to ingredients used in study drug
•15.Pregnant and Lactating females.

发起方

Welex Laboratories Pvt Ltd